< 1 minute read
Dec. 20, 2021

Compound 1: a RET inhibitor

compound 1

oral RET kinase inhibitor effective in tumor xenograft model from scaffold hopping & optimization ACS Medicinal Chemistry Letters Novartis Genomics Institute

drughunter.com
Drug Hunter Team

The Novartis RET inhibitor, compound 1, demonstrated robust oral in vivo efficacy in RET-driven tumor xenografts at low doses (10 mpk QD). RET inhibitors (selpercatinib and pralsetinib) have recently been approved in RET+ cancers based on significant efficacy in selected patients. Compound 1 was advanced through preclinical studies [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in